Why PolyPid Ltd.’s (PYPD) Stock Is Up 6.90%
As of Tuesday, September 01, PolyPid Ltd.’s PYPD share price has surged by 6.90%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Commentary & Analysis
Why PolyPid Ltd.’s (PYPD) Stock Is Up 7.47%
As of Monday, June 29, PolyPid Ltd.’s PYPD share price has surged by 7.47%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why PolyPid Ltd.’s (PYPD) Stock Is Up 5.83%
As of Monday, May 18, PolyPid Ltd.’s PYPD share price has surged by 5.83%, which has investors questioning if this is right time to sell.Michael Rose
Why PolyPid Ltd.’s (PYPD) Stock Is Up 5.46%
As of Tuesday, March 31, PolyPid Ltd.’s PYPD share price has surged by 5.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why PolyPid Ltd.’s (PYPD) Stock Is Up 5.15%
As of Wednesday, March 25, PolyPid Ltd.’s PYPD share price has surged by 5.15%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | PYPD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $102.2 | $589.9 | 21% |
|
| Shares Out (Mil) | 22.6 | 43.1 | 32% |
|
| Institutional Ownership | 61.8% | 83.7% | 39% |
|
| Float (Mil) | 12.2 | 45.1 | 22% |
|
| Beta | 1.39 | 0.73 | 79% |
|
| Avg Daily Volume (000s) | 98 | 300 | 36% |
|
| Price Change (52-week) |
46.7% | 65.3% | 81% |
|
| Growth | PYPD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 1.5% | (1.4%) | 42% |
|
| EPS (5yr) | 56.5% | 15.1% | 95 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.5%) | (15.0%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | $0.270 | ($0.890) | ($1.228) | |
| Month Ago EPS | $0.270 | ($0.890) | ($1.228) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | ($0.315) | ($1.428) | ($1.255) | |
| Year/Year Chg | (177.4%) | (57.4%) | (80.1%) | |
| Financials | PYPD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($32) | ($11) | 20% |
|
| EPS (TTM) | ($1.476) | ($0.700) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($6) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $91 | $508 | 20% |
|
| Valuation | PYPD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 18.63 | 2.51 | 95% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PYPD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (181.2%) | (22.5%) | 2% |
|
| ROE | (901.4%) | (21.8%) | 0% |
|
| Liabilities to Assets | 64.6% | 32.5% | 59% |
|
| F-Score | 3 | 3 | 18% |
|
PolyPid Ltd. did not pass any screens on 9/17/2026.
